OPKO Health, Inc. (OPK:NASDAQ) closed at $1.71 on November 10, 2026, unchanged on the day. The stock trades 8.1% below its 52-week high of $1.86 and 74.5% above its 52-week low of $0.980. Over the past year, it gained 28.6%. OPKO Health, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, OPK closed higher on 102 days (40%). Its best day was July 28, 2026 (+33.06%) and its worst was July 29, 2026 (-16.97%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 2 times.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone produ...
Find more stocks like OPK with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.